Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2407046 | 0.79 | CA1 (0.41) | CA1TSHR | |
| SCHEMBL2352012 | 0.77 | MMP1 (0.38) | SMN1; SMN2MMP1MMP2MMP3CA1 | |
| SCHEMBL2403991 | 0.76 | MMP1 (0.37) | SMN1; SMN2MMP1MMP2MMP3CA1 | |
| SCHEMBL5456859 | 0.74 | MMP1 (0.38) | SMN1; SMN2MMP1MMP2MMP3CA1 | |
| Methyl 2-Methylbutanoate SCHEMBL29222980 | 0.74 | MMP1 (0.47) | SMN1; SMN2MMP1MMP2MMP3CA1 | |
| SCHEMBL2466027 | 0.74 | MMP1 (0.38) | SMN1; SMN2MMP1MMP2MMP3CA1 | |
| SCHEMBL8565444 | 0.74 | SMN1; SMN2 (0.38) | SMN1; SMN2MMP1MMP2MMP3CA1 | |
| SCHEMBL8558146 | 0.74 | SMN1; SMN2 (0.38) | SMN1; SMN2MMP1MMP2MMP3CA1 | |
| SCHEMBL8565442 | 0.74 | SMN1; SMN2 (0.38) | SMN1; SMN2MMP1MMP2MMP3CA1 | |
| Methyl 2-Methylbutanoate SCHEMBL108113 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664418-B2 | Method for producing dialkylphosphinic acids and esters and salts thereof by means of acrylic acid derivatives and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2014-03-04 | — | — | US | disclosed |
| US-20110213052-A1 | Method for Producing Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Acrylic Acid Derivatives and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213052-A1 | Method for Producing Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Acrylic Acid Derivatives and Use Thereof | ACSL3, HAO2, AOC3 | SMN1; SMN2 4162/4885MMP1 4305/4885MMP2 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.